Akzo Nobel N.V.
Akzo Nobel N.V. (AKZOF) Financial Performance & Income Statement Overview
Analyze Akzo Nobel N.V. (AKZOF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Akzo Nobel N.V. (AKZOF) Income Statement & Financial Overview
Analyze Akzo Nobel N.V.’s AKZOF earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $2.61B | $2.62B | $2.67B | $2.78B |
| Cost of Revenue | $1.56B | $1.59B | $1.58B | $1.64B |
| Gross Profit | $1.05B | $1.03B | $1.08B | $1.14B |
| Gross Profit Ratio | $0.40 | $0.39 | $0.41 | $0.41 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $855.00M | $898.00M | $819.00M | $872.00M |
| Operating Expenses | $856.00M | $899.00M | $819.00M | $872.00M |
| Total Costs & Expenses | $2.42B | $2.49B | $2.40B | $2.52B |
| Interest Income | $0.00 | $0.00 | $12.00M | $16.00M |
| Interest Expense | $30.00M | $36.00M | $44.00M | $47.00M |
| Depreciation & Amortization | $94.00M | $94.00M | $96.00M | $92.00M |
| EBITDA | $298.00M | $225.00M | $380.00M | $369.00M |
| EBITDA Ratio | $0.11 | $0.09 | $0.14 | $0.13 |
| Operating Income | $192.00M | $127.00M | $264.00M | $269.00M |
| Operating Income Ratio | $0.07 | $0.05 | $0.10 | $0.10 |
| Other Income/Expenses (Net) | -$23.00M | -$32.00M | -$17.00M | -$26.00M |
| Income Before Tax | $169.00M | $95.00M | $247.00M | $239.00M |
| Income Before Tax Ratio | $0.06 | $0.04 | $0.09 | $0.09 |
| Income Tax Expense | $48.00M | $59.00M | $77.00M | $53.00M |
| Net Income | $107.00M | $21.00M | $163.00M | $177.00M |
| Net Income Ratio | $0.04 | $0.008 | $0.06 | $0.06 |
| EPS | $0.63 | $0.12 | $0.95 | $1.04 |
| Diluted EPS | $0.62 | $0.12 | $0.95 | $1.03 |
| Weighted Avg Shares Outstanding | $170.80M | $170.80M | $170.80M | $170.70M |
| Weighted Avg Shares Outstanding (Diluted) | $172.58M | $170.80M | $170.80M | $171.84M |
Over the last four quarters, Akzo Nobel N.V.'s revenue moved from $2.78B in Q2 2024 to $2.61B in Q1 2025. Operating income in Q1 2025 was $192.00M, with a strong operating margin of 7%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Akzo Nobel N.V. remained robust at $298.00M, reflecting operational efficiency. Net income rose to $107.00M, with an EPS of $0.63. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan